APOM and chronic kidney disease: The APOM/S1P complex has been demonstrated to reduce inflammation by inhibiting monocyte adhesion to the endothelium and maintaining endothelial barrier integrity.17 A meta-analysis identified a significant association between a polymorphism in the human APOM gene and coronary heart disease risk within the Chinese population.18 Moreover, a recent study demonstrated an independent association between lower circulating APOM levels and increased mortality in a non-CKD population of patients with chronic heart failure,19 highlighting the potential clinical significance of APOM.